DaShenLin Pharmaceutical Group CoSHSE:603233 +0.88%95 Interest Coverage is 20.94 as of Mar. 2026, which is 31% below its 10-year median of 30.22. GuruFocus rates SHSE:603233 with a GF Score™ of 95/100 and a GF Value™ of ¥18.75 (Fairly Valued). The stock has 4 warning signs investors should review. Among 453 Healthcare Providers & Services companies, DaShenLin Pharmaceutical Group Co ranks better than 75.28% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. DaShenLin Pharmaceutical Group Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥734 Mil. DaShenLin Pharmaceutical Group Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-35 Mil.
DaShenLin Pharmaceutical Group Co's interest coverage for the quarter that ended in Mar. 2026 was 20.94.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for DaShenLin Pharmaceutical Group Co's Interest Coverage or its related term are showing as below:
SHSE:603233'
s Interest Coverage Range Over the Past 10 Years
Min: 5.64 Med: 30.22 Max: 125.84
Current: 35.93
SHSE:603233's Interest Coverage is ranked better than 75.28% of 453
companies
in the Healthcare Providers & Services industry
Industry Median: 8
vs SHSE:603233: 35.93
DaShenLin Pharmaceutical Group Co (SHSE:603233) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
DaShenLin Pharmaceutical Group Co Interest Coverage Related Terms
DaShenLin Pharmaceutical Group Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
DaShenLin Pharmaceutical Group Co Interest Coverage Chart
DaShenLin Pharmaceutical Group Co Interest Coverage Competitor Comparison
For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaShenLin Pharmaceutical Group Co Interest Coverage vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where DaShenLin Pharmaceutical Group Co's Interest Coverage falls into.
DaShenLin Pharmaceutical Group Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a Interest Coverage of 20.94 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. This is 31% below median its historical median of 30.22. Over the past decade, DaShenLin Pharmaceutical Group Co's Interest Coverage has ranged from 5.64 to 125.84. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #112 out of 453 companies in the Healthcare Providers & Services industry, placing it in the top 24.7%.
Is DaShenLin Pharmaceutical Group Co's Interest Coverage too high?
DaShenLin Pharmaceutical Group Co's current Interest Coverage of 20.94 is 31% below median its 10-year median of 30.22. Over the past 10 years, this metric has ranged from a low of 5.64 to a high of 125.84. The Healthcare Providers & Services industry median Interest Coverage is 8.00. DaShenLin Pharmaceutical Group Co's value of 20.94 is 161.8% above this industry median. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #112 out of 453 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's Interest Coverage compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #112 out of 453 companies for Interest Coverage. This places DaShenLin Pharmaceutical Group Co in the top 25% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 8.00. DaShenLin Pharmaceutical Group Co's value of 20.94 is 161.8% above this benchmark. Historically, DaShenLin Pharmaceutical Group Co's own Interest Coverage has ranged from 5.64 to 125.84 over the past decade. While the company's 10-year median is 30.22 vs. the industry median of 8.00, DaShenLin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Healthcare Providers & Services company?
The median Interest Coverage among Healthcare Providers & Services companies is 8.00, based on 453 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaShenLin Pharmaceutical Group Co's current Interest Coverage of 20.94 is 161.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median Interest Coverage is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current Interest Coverage is 20.94, which is 31% below median its own 10-year median of 30.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.75, compared to a current price of ¥17.20 — trading 8.3% below its estimated fair value. The current Interest Coverage is 20.94, which is 31% below median its 10-year median of 30.22 and 161.8% above the Healthcare Providers & Services industry median of 8.00. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current Interest Coverage is 20.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥17.20 is trading 8.3% below its estimated GF Value™ of ¥18.75.
GuruFocus considers DaShenLin Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:603233:
Interest Coverage: 20.94 (31% below median its 10-year median of 30.22)
GF Value™: ¥18.75 vs. price of ¥17.20 (8.3% below fair value)
Industry Position: 161.8% above the Healthcare Providers & Services median (#112 of 453)
No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaShenLin Pharmaceutical Group Co Business Description
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
95GF Score
Get the complete analysis for SHSE:603233
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603233 has been successfully added to your 
